医学
放化疗
胶质母细胞瘤
肿瘤科
单核细胞
内科学
放射治疗
比例危险模型
养生
生存分析
败血症
探索性分析
免疫系统
总体生存率
危险系数
炎症
临床试验
无进展生存期
作者
Flavio Donnini,Pierpaolo Pastina,Giuseppe Battaglia,Salvatore Chibbaro,Alfonso Cerase,Valerio Nardone,Isacco Desideri,Francesco Pasqualetti,Alessandra Pascucci,Vincenzo D’Alonzo,Maria Antonietta Mazzei,Giuseppe Minniti,Anna Maria Giacomo,Paolo Tini
标识
DOI:10.1007/s11060-026-05830-x
摘要
Abstract Purpose Routine blood counts may capture treatment-related host immune perturbation in glioblastoma, but most studies rely on static pretreatment values. We investigated whether the intra-individual preservation of circulating monocytes during chemoradiotherapy provides prognostic information beyond established clinical factors and other hematologic trajectories. Methods We retrospectively analyzed adults with histologically confirmed IDH-wildtype glioblastoma treated with radiotherapy and concurrent temozolomide. Absolute monocyte counts obtained before and at the end of chemoradiotherapy were used to define monocytic resilience as log2(post-treatment/pre-treatment monocyte ratio). Overall survival (OS) was the primary endpoint. Cox models adjusted for MGMT promoter methylation, gross total resection, Karnofsky Performance Status, and age. The ratio was analyzed continuously for primary inference. A post/pre ratio of 0.75 was additionally evaluated as an exploratory, clinically interpretable threshold for two-group Kaplan–Meier visualization and sensitivity analysis. Results Among 127 patients, 115 had complete monocyte trajectories and OS data. The continuous monocyte post/pre ratio was independently associated with OS in the primary adjusted model (HR 0.53 per doubling, 95% CI 0.37–0.76; p = 0.00051). Using the exploratory 0.75 threshold, 52 patients had low resilience (< 0.75) and 63 had preserved resilience (≥ 0.75), with median OS of 10.2 and 17.3 months, respectively (log-rank p = 0.00064). Preserved resilience was associated with lower mortality in univariable Cox analysis (HR 0.50, 95% CI 0.34–0.75; p = 0.00080). Bootstrap resampling showed that outcome-optimized cut-points clustered around this region (median 0.74; IQR 0.70–0.81), although the threshold remains exploratory and requires external validation. Conclusions Preservation or recovery of circulating monocytes during chemoradiotherapy identifies a favorable host-response phenotype in IDH-wildtype glioblastoma. This dynamic signal appears distinct from baseline monocyte burden, treatment-related lymphocyte change, systemic inflammatory imbalance, and measured corticosteroid exposure. External prospective validation and immune phenotyping are required before clinical use.
科研通智能强力驱动
Strongly Powered by AbleSci AI